Showing results (281-290 of 324) with videos related to
Sort By:
Pageof 33
British Journal of Cancer|April 21, 2011
Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma: the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) studyN Penel, M V Glabbeke, S Mathoulin-Pelissier, et al.Biochimica Et Biophysica Acta|January 20, 1998
Inhibition of phospholipid signalling and proliferation of Swiss 3T3 cells by the wortmannin analogue demethoxyviridinM J Cross, M N Hodgkin, J A Plumb, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2001
Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancerL R Kelland, V Smith, M Valenti, et al.Lancet (London, England)|November 14, 2001
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I studyA T van Oosterom, I Judson, J Verweij, et al.British Journal of Cancer|September 1, 1999
Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II. CRC Phase I/II CommitteeC J Twelves, C Gardner, A Flavin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies GroupE Briasoulis, I Judson, N Pavlidis, et al.British Journal of Cancer|September 29, 2004
Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumoursM J A de Jonge, S Kaye, J Verweij, et al.Oncogene|August 19, 2007
A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1DS Rayter, R Elliott, J Travers, et al.Oncogene|May 20, 2020
Correction: A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1DS Rayter, R Elliott, J Travers, et al.Clinical Sarcoma Research|August 11, 2017
Radiation induced angiosarcoma of the breast: outcomes from a retrospective case seriesR B Cohen-Hallaleh, H G Smith, R C Smith, et al.Pageof 33